Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies
Yu Han,1–3 Jianjun Chen,2–4 Dezhi Zou,1–3 Peng Zheng,1–3 Qi Li,1–3 Haiyang Wang,1–3 Pengfei Li,1–3 Xinyu Zhou,1–3 Yuqing Zhang,1–3 Yiyun Liu,1–3 Peng Xie1–3 1Department of Neurology, The Fi...
Guardado en:
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2016
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/0da51716093c457cb0ed3f03d07b17d8 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:0da51716093c457cb0ed3f03d07b17d8 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:0da51716093c457cb0ed3f03d07b17d82021-12-02T08:51:17ZEfficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies1178-2021https://doaj.org/article/0da51716093c457cb0ed3f03d07b17d82016-11-01T00:00:00Zhttps://www.dovepress.com/efficacy-of-ketamine-in-the-rapid-treatment-of--major-depressive-disor-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Yu Han,1–3 Jianjun Chen,2–4 Dezhi Zou,1–3 Peng Zheng,1–3 Qi Li,1–3 Haiyang Wang,1–3 Pengfei Li,1–3 Xinyu Zhou,1–3 Yuqing Zhang,1–3 Yiyun Liu,1–3 Peng Xie1–3 1Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, 2Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, 3Chongqing Key Laboratory of Neurobiology, 4Institute of Life Sciences, Chongqing Medical University, Chongqing, People’s Republic of China Background: An increasing number of studies are reporting that ketamine could be treated as a novel antidepressant for major depressive disorder (MDD). Therefore, we performed this meta-analysis to comprehensively and systematically assess the efficacy of ketamine for treating patients with MDD. Method: Randomized, double-blind, placebo-controlled studies on ketamine versus placebo for treating MDD were searched up to April 2016 in medical databases (PubMed, CCTR, Web of Science, Embase, CBM-disc, and CNKI). Three treatment time points (24 and 72 h, and day 7) were chosen. Response and remission rates were the main outcomes. The random effects model was used. An intention-to-treat analysis was conducted. Results: Nine high-quality studies that included 368 patients were selected to compare the efficacy of ketamine to placebo. The therapeutic effects of ketamine at 24 and 72 h, and day 7 were found to be significantly better than placebo. Response and remission rates in the ketamine group at 24 and 72 h, and day 7 were 52.2% and 20.6%; 47.9% and 23.8%; and 39.8% and 26.2%, respectively. No significant heterogeneity existed, and the Egger’s test showed no publication bias. Conclusion: These results indicated that ketamine could yield a good efficacy in the rapid treatment of MDD. Future large-scale clinical studies are needed to confirm our results and investigate the mid- and long-term efficacy of ketamine in treating MDD. Keywords: major depressive disorder, MDD, ketamine, meta-analysisHan YChen JZou DZheng PLi QWang HLi PZhou XZhang YLiu YXie PDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 12, Pp 2859-2867 (2016) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
| spellingShingle |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Han Y Chen J Zou D Zheng P Li Q Wang H Li P Zhou X Zhang Y Liu Y Xie P Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies |
| description |
Yu Han,1–3 Jianjun Chen,2–4 Dezhi Zou,1–3 Peng Zheng,1–3 Qi Li,1–3 Haiyang Wang,1–3 Pengfei Li,1–3 Xinyu Zhou,1–3 Yuqing Zhang,1–3 Yiyun Liu,1–3 Peng Xie1–3 1Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, 2Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, 3Chongqing Key Laboratory of Neurobiology, 4Institute of Life Sciences, Chongqing Medical University, Chongqing, People’s Republic of China Background: An increasing number of studies are reporting that ketamine could be treated as a novel antidepressant for major depressive disorder (MDD). Therefore, we performed this meta-analysis to comprehensively and systematically assess the efficacy of ketamine for treating patients with MDD. Method: Randomized, double-blind, placebo-controlled studies on ketamine versus placebo for treating MDD were searched up to April 2016 in medical databases (PubMed, CCTR, Web of Science, Embase, CBM-disc, and CNKI). Three treatment time points (24 and 72 h, and day 7) were chosen. Response and remission rates were the main outcomes. The random effects model was used. An intention-to-treat analysis was conducted. Results: Nine high-quality studies that included 368 patients were selected to compare the efficacy of ketamine to placebo. The therapeutic effects of ketamine at 24 and 72 h, and day 7 were found to be significantly better than placebo. Response and remission rates in the ketamine group at 24 and 72 h, and day 7 were 52.2% and 20.6%; 47.9% and 23.8%; and 39.8% and 26.2%, respectively. No significant heterogeneity existed, and the Egger’s test showed no publication bias. Conclusion: These results indicated that ketamine could yield a good efficacy in the rapid treatment of MDD. Future large-scale clinical studies are needed to confirm our results and investigate the mid- and long-term efficacy of ketamine in treating MDD. Keywords: major depressive disorder, MDD, ketamine, meta-analysis |
| format |
article |
| author |
Han Y Chen J Zou D Zheng P Li Q Wang H Li P Zhou X Zhang Y Liu Y Xie P |
| author_facet |
Han Y Chen J Zou D Zheng P Li Q Wang H Li P Zhou X Zhang Y Liu Y Xie P |
| author_sort |
Han Y |
| title |
Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies |
| title_short |
Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies |
| title_full |
Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies |
| title_fullStr |
Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies |
| title_full_unstemmed |
Efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies |
| title_sort |
efficacy of ketamine in the rapid treatment of major depressive disorder: a meta-analysis of randomized, double-blind, placebo-controlled studies |
| publisher |
Dove Medical Press |
| publishDate |
2016 |
| url |
https://doaj.org/article/0da51716093c457cb0ed3f03d07b17d8 |
| work_keys_str_mv |
AT hany efficacyofketamineintherapidtreatmentofmajordepressivedisorderametaanalysisofrandomizeddoubleblindplacebocontrolledstudies AT chenj efficacyofketamineintherapidtreatmentofmajordepressivedisorderametaanalysisofrandomizeddoubleblindplacebocontrolledstudies AT zoud efficacyofketamineintherapidtreatmentofmajordepressivedisorderametaanalysisofrandomizeddoubleblindplacebocontrolledstudies AT zhengp efficacyofketamineintherapidtreatmentofmajordepressivedisorderametaanalysisofrandomizeddoubleblindplacebocontrolledstudies AT liq efficacyofketamineintherapidtreatmentofmajordepressivedisorderametaanalysisofrandomizeddoubleblindplacebocontrolledstudies AT wangh efficacyofketamineintherapidtreatmentofmajordepressivedisorderametaanalysisofrandomizeddoubleblindplacebocontrolledstudies AT lip efficacyofketamineintherapidtreatmentofmajordepressivedisorderametaanalysisofrandomizeddoubleblindplacebocontrolledstudies AT zhoux efficacyofketamineintherapidtreatmentofmajordepressivedisorderametaanalysisofrandomizeddoubleblindplacebocontrolledstudies AT zhangy efficacyofketamineintherapidtreatmentofmajordepressivedisorderametaanalysisofrandomizeddoubleblindplacebocontrolledstudies AT liuy efficacyofketamineintherapidtreatmentofmajordepressivedisorderametaanalysisofrandomizeddoubleblindplacebocontrolledstudies AT xiep efficacyofketamineintherapidtreatmentofmajordepressivedisorderametaanalysisofrandomizeddoubleblindplacebocontrolledstudies |
| _version_ |
1718398346794631168 |